Year: 2026

60 Degrees Pharmaceuticals Announces 2025 Annual Results

Written by Customer Service on March 31, 2026. Posted in Earnings Releases And Operating Results.

FY 2025 net product revenues increased 65% to $1,005,000 Current shelf capacity exhausted after raise of $4 million through an ATM facilityWASHINGTON, March 31, 2026 (GLOBE NEWSWIRE) — 60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP; SXTPW) (the “Company”), a pharmaceutical company focused on developing new medicines for vector-borne disease, reported today its financial results for the 2025 fiscal year ended December 31, 2025. Financial Highlights for the Fiscal Year Ended December 31, 2025:Net product revenues increased 65% from $607.6 thousand in 2024 to $1.0 million in 2025, driven by rising sales, price increases, and fewer returns. The Company achieved a gross profit of approximately $223.8 thousand in 2025, compared with approximately $222.8 thousand in 2024. Gross profit remained relatively stable despite inventory write-offs...

4basebio announces major expansion to support the growing demand of RUO and HQ synthetic DNA with lease of an innovation hub and manufacturing facility in Cambridge, UK

Written by Customer Service on March 31, 2026. Posted in Public Companies.

4basebio PLC (“4basebio” or the “Company”) Cambridge, UK, 31 March 2026 – 4basebio PLC (AIM: 4BB), a specialist in synthetic DNA manufacturing and nucleic acids for next-generation therapeutics, announces a significant expansion into a new innovation hub and manufacturing facility in Cambridge, UK, supporting growing demand for research and high-quality grade manufacturing of synthetic DNA for gene and cell therapies, mRNA vaccines, genome editing, or DNA vaccines. 31-35 Saxon Way, Bar Hill, is being leased from Peterhouse, the University of Cambridge’s oldest college, who have a long tradition of supporting academic excellence and scientific innovation. 4basebio is expected to move into the facility late summer 2026, once the building has been developed. The new facility will provide approximately 26,500 square...

Aya Gold & Silver Reports Record Results for Q4-2025 and Full Year 2025

Written by Customer Service on March 31, 2026. Posted in Public Companies.

Record Revenue, Net Income and Cash Flow from Operations MONTREAL, March 31, 2026 (GLOBE NEWSWIRE) — Aya Gold & Silver Inc. (TSX: AYA; OTCQX: AYASF) (“Aya” or the “Corporation”) today announced its financial and operational results for the fourth quarter and full year ended December 31, 2025. All amounts are in U.S. dollars unless otherwise noted. Full Year and Q4 2025 Highlights Financial HighlightsFull-year revenue of $202M in 2025, up five-fold, year-over-year (“YoY”), on 4.9 million silver equivalent ounces (“Moz AgEq”) sold, (up 223%), at a higher average net realized AgEq price of $41.61/oz (up 60%). Q4-2025 revenue of $75M, up 39% quarter-over-quarter (“QoQ”), driven by a higher average net realized AgEq price of $58.39/oz (up 47% QoQ and 111% YoY), as well as initial sales of the...

Seyond Releases 2025 Annual Report | Inflection Point Emerges: Multi-Engine Growth Unlocks Unlimited Potential of Physical AI

Written by Customer Service on March 31, 2026. Posted in Public Companies.

SUNNYVALE, Calif., March 31, 2026 (GLOBE NEWSWIRE) — On March 31, 2026, Seyond (02665.HK) announced its audited full-year results for 2025. During the reporting period, the company’s annual lidar shipments exceeded 332,000 units, representing a year-on-year increase of 45.0%. Along with the rapid expansion of business scale, operational quality also improved significantly: gross profit turned positive from a loss in 2024, with the gross profit margin rising to 7.9%. This milestone marks that, driven by economies of scale, cost optimization, and product structure upgrading, Seyond has entered a new phase of high-quality growth.Continuous Release of Economies of Scale, Comprehensive Leap in Operational Efficiency According to International Financial Reporting Standards (IFRS), Seyond’s annual revenue reached approximately...

Biomea Fusion Announces First Patient Dosed in Newly Initiated Phase II Programs Enrolling Type 2 Diabetes Patients Failing on Standard-of-Care Therapies

Written by Customer Service on March 31, 2026. Posted in Public Companies.

COVALENT-211 Phase II enrolling insulin-deficient type 2 diabetes patients COVALENT-212 Phase II enrolling type 2 diabetes patients uncontrolled with a GLP-1 receptor agonist-based therapyTopline 26-week primary endpoint data from both Phase II studies anticipated 4Q 2026 SAN CARLOS, Calif., March 31, 2026 (GLOBE NEWSWIRE) — Biomea Fusion, Inc. (“Biomea” or “Biomea Fusion” or “the Company”) (Nasdaq: BMEA), a clinical-stage diabetes and obesity medicines company, today announced that the first patient has been dosed in its newly initiated Phase II programs, COVALENT-211 and COVALENT-212, evaluating icovamenib in patients with type 2 diabetes (“T2D”), marking a key step in advancing icovamenib into Phase II development in targeted patient populations failing standard-of-care therapies as established in the clinical trial COVALENT-111. “These...

Atos Advances AI-Ready Digital Transformation with Lumen Network as a Service

Written by Customer Service on March 31, 2026. Posted in Public Companies.

Atos Advances AI-Ready Digital Transformation with Lumen Network as a Service Irving, Texas, USA – March 31, 2026 – Atos, a global leader of AI-powered digital transformation today announced a significant advancement in its digital infrastructure strategy through expanded adoption of Lumen’s Network as a Service (NaaS) across its North America data centers, marking a strategic step in its digital transformation journey toward AI-ready, adaptive infrastructure. The initiative delivers greater agility, cost efficiency, and resiliency while enabling seamless connectivity to cloud and edge ecosystems. As enterprises accelerate their digital transformation and adoption of AI, automation, and agentic workflows, network infrastructure must respond in real time. Lumen’s on-demand, consumption-based NaaS provides Atos with a dynamic foundation...

Chagee Announces Fourth Quarter and Full Year 2025 Unaudited Financial Results

Written by Customer Service on March 31, 2026. Posted in Public Companies.

SHANGHAI, March 31, 2026 (GLOBE NEWSWIRE) — Chagee Holdings Limited (NASDAQ: CHA) (“Chagee” or the “Company”), a leading premium tea drinks brand serving healthy and delicious freshly-made tea drinks, today announced its unaudited financial results for the fourth quarter and full year ended December 31, 2025. Fourth Quarter and Full Year 2025 Operational Highlights1As of December 31, 2025, there were 7,453 teahouses within the Company’s teahouse network in Greater China and overseas, representing a 15.7% increase in the number of teahouses as of December 31, 2024. Total GMV generated in the fourth quarter of 2025 was RMB7,322.9 million. Geographically, total GMV generated in overseas markets was RMB371.9 million in the fourth quarter of 2025, representing an 84.6% year-over-year increase; total GMV generated in Greater China market...

Bitfarms Reports Fiscal Year 2025 Results

Written by Customer Service on March 31, 2026. Posted in Public Companies.

Commercialization efforts underway at Panther Creek (PA), Sharon (PA), and Moses Lake (WA) $520 million of cash and Bitcoin on the balance sheet to support site development as of March 27, 2026 Continuing to advance 2.2 GW development pipeline across Washington state, Pennsylvania and Québec sites Shareholders approved redomiciliation to the U.S. from Canada; closing of the transaction expected on or about April 1, 2026; Bitfarms will rebrand to Keel Infrastructure on closing TORONTO, Ontario and NEW YORK, March 31, 2026 (GLOBE NEWSWIRE) — Bitfarms Ltd. (Nasdaq/TSX: BITF) (“Bitfarms” or the “Company”), a North American digital and energy infrastructure company, today reported its financial results for the year ended December 31, 2025. All financial references are in U.S. dollars. The Company has transitioned...

YXT.com Reports Full Year 2025 Unaudited Financial Results

Written by Customer Service on March 31, 2026. Posted in Public Companies.

SUZHOU, China, March 31, 2026 (GLOBE NEWSWIRE) — YXT.com Group Holding Limited (NASDAQ: YXT) (“YXT.com” or the “Company”), a provider of AI-enabled enterprise productivity solutions, today announced its unaudited financial results for the full year ended December 31, 2025. Financial Highlights for the Full Year of 2025Total revenues were RMB340.2 million (US$48.7 million) for the full year of 2025, compared with RMB331.2 million in the prior year, representing an increase of 2.7%. Gross margin was 68.3% for the full year of 2025, compared with 61.8% in the prior year, representing an increase of 6.5 percentage points. Net loss was RMB158.9 million (US$22.7 million), compared with RMB92.1 million in the prior year. Adjusted net loss was RMB146.6 million (US$21.0 million), compared with RMB199.3 million in the prior year, representing...

Biogen to Acquire Apellis, Enhancing the Company’s Growth Portfolio in Immunology and Rare Disease, Bolstering Growth Outlook and Accelerating Expansion into Nephrology

Written by Customer Service on March 31, 2026. Posted in Mergers And Acquisitions.

Acquisition will bring two differentiated commercialized immunology medicines to Biogen with EMPAVELI® FDA-approved in three indications, including two rare kidney diseases, and SYFOVRE® FDA-approved in geographic atrophy, an immune-mediated retinal disease Bringing together Biogen and Apellis’ commercialization capabilities will maximize the potential of both EMPAVELI® and SYFOVRE®, while Apellis’ talent and expertise will accelerate Biogen’s entry into nephrology and augment launch readiness for felzartamab, currently in Phase 3 Acquisition is expected to bolster Biogen’s near-and long-term growth prospects, adding immediate revenue from two products with significant growth potential; 2025 net product revenue for EMPAVELI® and SYFOVRE® together was $689 million, expected to grow at a rate in the mid-to-high teens at least through 2028 Biogen...

Year: 2026

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals